Let us put you in front of a doctor who specializes in treating your form of cancer.
Get Help NowGet help obtaining veteran benefits for mesothelioma and asbestos illnesses.
Get VA BenefitsGet help finding an attorney who will fight to get you the compensation you and your family deserve
Get Assistance
Standard of care treatment for malignant pleural mesothelioma may be changing soon, based on discussions last week at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago.
Read More
Thoracic surgeon and mesothelioma specialist Dr. Andrea Wolf likes to use the analogy that you don’t need a randomized trial to know that skydivers with a parachute generally will fare…
Read More
The United Kingdom needs a more universal, multidisciplinary approach to the treatment of malignant pleural mesothelioma to improve survival times and overcome the no-hope attitude that too often surrounds…
Read More
Taking common fish oil supplements or even eating a particular fish may reduce the effectiveness of chemotherapy for cancer patients, including those with malignant mesothelioma, according to a new study.
Read More
A groundbreaking immunotherapy drug that effectively treats skin cancer stopped tumor growth in 76 percent of patients diagnosed with malignant pleural mesothelioma, a recent study shows. Researchers at the…
Read More
Aggressive pleurectomy/decortication surgery, while often recommended, will cause a significant decrease in pulmonary function with early-stage mesothelioma patients whose symptoms were previously minimal. More symptomatic patients with advanced disease will…
Read More
The U.S. Food and Drug Administration (FDA) granted orphan drug designation last week to the immunotherapy vaccine CRS-207, moving it one step closer to changing the way malignant pleural mesothelioma…
Read More
Although no definitive cure is in sight, the treatment of malignant pleural mesothelioma has entered a promising, much-anticipated phase that goes beyond the multimodal approach that has been the…
Read More
Federal approval of the highly-touted immunotherapy drug Opdivo for advanced squamous non-small cell lung cancer may signal good news for malignant pleural mesothelioma patients. The U.S. Food and Drug…
Read More
More than 30 percent of patients with epithelioid mesothelioma, the most common cellular strain of this cancer. lived for five years or more after a multidisciplinary treatment approach in England,…
Read More
Jul 14, 2017
This site complies with the HONcode standard for trustworthy health information: Verify Here.
